Woman paddleboarding on a lake with forested mountains in the background under clear sky.Woman paddleboarding on a lake with forested mountains in the background under clear sky.

Guiding patient care in ambiguous melanocytic lesions

MyPath Melanoma is a gene expression profile (GEP) test that provides clarity in managing patients with ambiguous melanocytic lesions.

GEP provides objective information to clarify malignant potential

When patients are diagnosed with routine nevi or malignant melanoma, the treatment plans are clearly defined by medical guidelines. However, there is a lack of clarity and standardization in the most appropriate management plan for patients with ambiguous, atypical, and abnormal melanocytic lesions. MyPath Melanoma can clarify the underlying malignant potential of the lesion allowing providers to escalate or de-escalate surgical treatment and follow-up frequency.

Bearded man with glasses in blue blazer and shirt speaking in front of a blurred abstract painting.

Aiding dermatology providers in determining malignant potential

In recent studies and case reports, 1,2 ancillary diagnostic GEP testing has aided dermatologists in determining the malignant potential of these challenging melanocytic lesions. This allows providers to confidently align patient management to the malignant potential as determined by GEP.

MyPath Melanoma GEP testing provides an objective assessment of the expression levels of 23 genes and applies a proprietary algorithm to classify the lesion as suggestive of benign or suggestive of malignant.3 Numerous studies have demonstrated high sensitivity and specificity 4-8 and clinical utility 9–12 of GEP testing for dermatology providers.

Flowchart showing melanoma diagnosis process and patient management based on benign or malignant suggestion.

Examples of cases that are appropriate for testing

White magnifying glass highlighting an illustrated virus or germ on blue gradient background.

Borderline or uncertain diagnosis

  • Atypical intraepidermal melanocytic proliferation (AIMP)

  • Borderline or severely dysplastic nevus

  • Cannot exclude melanoma in situ

  • Cannot exclude early-evolving invasive melanoma

Minimalist white line drawing of a person swallowing a red pill on a blue background.

Uncertain malignant potential

  • Atypical Spitz tumor

  • Melanocytic tumor of uncertain malignant potential (MELTUMP)

Computer screen icon with a medical cross and text lines, symbolizing healthcare or medical records.

Conflicting clinical and/or histopathological features

  • Highly concerning clinical history or dermoscopic features

  • Critical mismatch between clinical and histopathological findings

  • Equivocal, ambigious, or indeterminate result from ancillary testing such as IHC, FISH, or CGH

Icon of a clipboard behind a stethoscope on a blue gradient background.

Treatment recommendation

  • Surgical management in cosmetically sensitive areas

  • Follow-up management decisions

  • Recommendation to re excise without definitive diagnosis for melanoma

Explore case studies

Get started with MyPath Melanoma